- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00058279
Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma
MDX-CTLA4 Combined With IL-2 for Patients With Metastatic Melanoma
RATIONALE: Biological therapies, such as MDX-010, work in different ways to stimulate the immune system and stop tumor cells from growing. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Combining monoclonal antibody therapy with interleukin-2 may kill more tumor cells.
PURPOSE: Phase I/II trial to study the effectiveness of combining monoclonal antibody therapy with interleukin-2 in treating patients who have metastatic melanoma.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
OBJECTIVES:
- Determine the maximum tolerated dose (MTD) of anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody (MDX-CTLA4) in combination with high-dose interleukin-2 (IL-2) in patients with metastatic melanoma. (Phase I is closed to accrual as of 4/13/2004).
- Determine the activity of MDX-CTLA4 administered at the MTD with high-dose IL-2 in these patients.
- Determine whether the administration of IL-2 alters the pharmacokinetics of MDX-CTLA4 in these patients.
- Determine the safety and adverse event profile of this regimen in these patients.
OUTLINE: This is an open-label, dose-escalation study of anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody (MDX-CTLA4).
- Phase I: Patients receive MDX-CTLA4 IV on days 0, 21, and 42. Patients also receive high-dose interleukin-2 (IL-2) IV over 15 minutes every 8 hours for up to 15 doses beginning on days 22 and 43. Treatment repeats every 63 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients with an ongoing partial response and no greater than grade 1 toxicity may receive additional courses of therapy. Patients who require discontinuation of MDX-CTLA4 due to toxicity may continue receiving IL-2 at the discretion of the investigator.
Cohorts of 3-6 patients receive escalating doses of MDX-CTLA4 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. (Phase I is closed to accrual as of 4/13/2004).
- Phase II: Patients receive treatment as in phase I at the MTD of MDX-CTLA4. Patients who achieve a partial or complete response and later develop recurrent or progressive disease may be retreated at the same dose.
Patients are followed at 3 weeks, every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter.
PROJECTED ACCRUAL: A total of 3-51 patients (3-18 for phase I and 19-33 for phase II) will be accrued for this study within 1 year. (Phase I is closed to accrual as of 4/13/2004).
Studientyp
Phase
- Phase 2
- Phase 1
Kontakte und Standorte
Studienorte
-
-
Maryland
-
Bethesda, Maryland, Vereinigte Staaten, 20892-1182
- Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
DISEASE CHARACTERISTICS:
Histologically confirmed stage IV melanoma
- Mucosal or ocular melanoma also eligible
Clinically evaluable disease
- At least 1 site of measurable disease
PATIENT CHARACTERISTICS:
Age
- 16 and over
Performance status
- ECOG 0-1
Life expectancy
- At least 3 months
Hematopoietic
- WBC at least 2,500/mm^3
- Absolute neutrophil count at least 1,500/mm^3
- Platelet count at least 100,000/mm^3
- Hemoglobin at least 10 g/dL
- Hematocrit at least 30%
Hepatic
- Bilirubin no greater than upper limit of normal (ULN)* (less than 3.0 mg/dL in patients with Gilbert's syndrome)
- AST no greater than 3 times ULN*
- Hepatitis B surface antigen negative
- Hepatitis C antibody nonreactive
- No evidence or history of significant hepatic disease that would preclude safe administration of high-dose IL-2 NOTE: *Unless attributable to disease
Renal
- Creatinine no greater than 2.0 mg/dL
- No evidence or history of significant renal disease that would preclude safe administration of high-dose IL-2
Cardiovascular
- No evidence or history of significant cardiac disease that would preclude safe administration of high-dose IL-2
- Thallium stress test normal (for patients over 50 years of age or with a history of cardiovascular disease)
Pulmonary
- No evidence or history of significant pulmonary disease that would preclude safe administration of high-dose IL-2
Immunologic
- HIV negative
- No autoimmune disease (including uveitis and autoimmune inflammatory eye disease)
- No active infection
Other
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix
- No evidence or history of significant gastrointestinal disease that would preclude safe administration of high-dose IL-2
- No evidence or history of psychiatric disease that would preclude safe administration of high-dose IL-2
- No other underlying medical condition that would make the administration of the study drug hazardous or obscure the interpretation of adverse events
- No other concurrent medical condition that would preclude study entry
PRIOR CONCURRENT THERAPY:
Biologic therapy
- At least 3 weeks since prior immunotherapy for melanoma and recovered
- No prior anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody (MDX-CTLA4)
- No prior high-dose (at least 600,000 IU/kg every 8 hours) interleukin-2 (IL-2)
Chemotherapy
- At least 3 weeks since prior chemotherapy for melanoma and recovered
- No concurrent chemotherapy
Endocrine therapy
- At least 3 weeks since prior hormonal therapy for melanoma and recovered
- At least 4 weeks since prior corticosteroids
- No concurrent systemic or topical corticosteroids
Radiotherapy
- At least 3 weeks since prior radiotherapy for melanoma and recovered
Surgery
- Not specified
Other
- No concurrent immunosuppressive agents (e.g., cyclosporine or its analog)
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Maskierung: Keine (Offenes Etikett)
Mitarbeiter und Ermittler
Sponsor
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Maker AV, Phan GQ, Attia P, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Haworth LR, Levy C, Kleiner D, Mavroukakis SA, Yellin M, Rosenberg SA. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol. 2005 Dec;12(12):1005-16. doi: 10.1245/ASO.2005.03.536. Epub 2005 Oct 21.
- Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen TT, Berman DM, Wolchok JD. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol. 2015 Jun 10;33(17):1889-94. doi: 10.1200/JCO.2014.56.2736. Epub 2015 Feb 9.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Neubildungen nach histologischem Typ
- Neubildungen
- Neuroektodermale Tumoren
- Neoplasmen, Keimzelle und Embryonal
- Neubildungen, Nervengewebe
- Neuroendokrine Tumoren
- Nävi und Melanome
- Melanom
- Molekulare Mechanismen der pharmakologischen Wirkung
- Antiinfektiva
- Antivirale Mittel
- Anti-HIV-Agenten
- Antiretrovirale Mittel
- Antineoplastische Mittel
- Antineoplastische Mittel, immunologische
- Immun-Checkpoint-Inhibitoren
- Aldesleukin
- Ipilimumab
Andere Studien-ID-Nummern
- CDR0000287211
- NCI-03-C-0109
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur aldesleukin
-
National Cancer Institute (NCI)AbgeschlossenMetastasierendes Melanom | NierenzellkrebsVereinigte Staaten
-
Cancer Biotherapy Research GroupUnbekanntNierenkrebsVereinigte Staaten
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI); Chiron CorporationAbgeschlossenNierenkrebsVereinigte Staaten
-
Blumenthal Cancer Center at Carolinas Medical CenterUnbekannt
-
Cancer Biotherapy Research GroupUnbekanntLungenkrebsVereinigte Staaten
-
St. Anna KinderkrebsforschungUnbekannt
-
National Cancer Institute (NCI)Abgeschlossen
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)AbgeschlossenLymphomVereinigte Staaten
-
European Organisation for Research and Treatment...AbgeschlossenLeukämieFrankreich, Belgien, Niederlande, Italien, Österreich, Kroatien
-
University of Southern CaliforniaNational Cancer Institute (NCI)BeendetInhaliertes Interleukin-2 bei der Behandlung von Patienten mit metastasiertem oder inoperablem KrebsNicht näher bezeichneter erwachsener solider Tumor, protokollspezifischVereinigte Staaten